EI
ADPT icon

EAM Investors’s Adaptive Biotechnologies ADPT Stock Holding History

EAM Investors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-351,297
Closed -$5.71M – 275
2025
Q4 		$5.71M Sell
351,297
-7,357
-2% -$120K 0.64% 41
2025
Q3 		$5.28M Buy
358,654
+37,081
+12% +$452K 0.61% 50
2025
Q2 		$3.75M Buy
+321,573
New +$2.92M 0.57% 85
2021
Q1 		– Sell
-28,310
Closed -$1.67M – 324
2020
Q4 		$1.67M Buy
+28,310
New +$1.46M 0.27% 171

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EAM Investors's ADPT Position: Q1 2026 in Review

EAM Investors sold out of Adaptive Biotechnologies (ADPT) in Q1 2026, closing a stake of 351,297 shares — an estimated $5.71M sold.

EAM Investors first reported a position in ADPT in Q4 2020 and held it in 4 quarters. The position peaked at $5.71M in Q4 2025. 298 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • EAM Investors reported no remaining Adaptive Biotechnologies position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 351,297 Adaptive Biotechnologies shares in Q1 2026, an estimated $5.71M.
  • EAM Investors first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 4 quarters.
  • EAM Investors's Adaptive Biotechnologies position peaked at $5.71M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.